secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001104659-25-077659
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem's partner reports 68.8% ORR for VS-7375 in KRAS G12D NSCLC at RP2D
---------------------------------------------------------------------------

- ORR of 68.8% (11/16) and DCR of 93.8% (15/16) at recommended Phase 2 dose of 600 mg QD in NSCLC patients.
- Across all dose levels, ORR 57.7% (15/26) and DCR 88.5% (23/26) in evaluable advanced NSCLC patients.
- Safety profile: TRAEs in 27.5% (39/142), Grade≥3 SAEs in 7.7% (11/142); no TRAE-related deaths; 6 discontinuations.
- Data to be presented in mini oral at IASLC WCLC on Sept 7, 2025; builds on prior ASCO ORR of 42% (n=12).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/0001104659-25-077659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/tm2523452d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-077659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer